Cambinol
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 540055

CAS#: 14513-15-6

Description: Cambinol is a SIRT inhibitor. It inhibits expression of pro-inflammatory cytokines, improves survival in models of endotoxic shock and septic shock, and prevents proliferation and increases differentiation and senescence in hepatocellular carcinoma cells.


Price and Availability

Size
Price

50mg
USD 450
500mg
USD 1650
5g
USD 4850
Size
Price

100mg
USD 750
1g
USD 2950
Size
Price

200mg
USD 1150
2g
USD 3950

Cambinol, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 540055
Name: Cambinol
CAS#: 14513-15-6
Chemical Formula: C21H16N2O2S
Exact Mass: 360.0932
Molecular Weight: 360.43
Elemental Analysis: C, 69.98; H, 4.47; N, 7.77; O, 8.88; S, 8.89


Synonym: SIRT 1/2 inhibitor IV; NSC112546; NSC-112546; NSC 112546; SIRT1 Inhibitor II; SIRT2 Inhibitor VI;

IUPAC/Chemical Name: 5-((2-hydroxynaphthalen-1-yl)methyl)-6-phenyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one

InChi Key: RVNSQVIUFZVNAU-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H16N2O2S/c24-18-11-10-13-6-4-5-9-15(13)16(18)12-17-19(14-7-2-1-3-8-14)22-21(26)23-20(17)25/h1-11,24H,12H2,(H2,22,23,25,26)

SMILES Code: O=C(C(CC1=C2C=CC=CC2=CC=C1O)=C(C3=CC=CC=C3)N4)NC4=S


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Lugrin J, Ciarlo E, Santos A, Grandmaison G, dos Santos I, Le Roy D, Roger T. The sirtuin inhibitor cambinol impairs MAPK signaling, inhibits inflammatory and innate immune responses and protects from septic shock. Biochim Biophys Acta. 2013 Jun;1833(6):1498-510. doi: 10.1016/j.bbamcr.2013.03.004. Epub 2013 Mar 13. PubMed PMID: 23499872.

2: Figuera-Losada M, Stathis M, Dorskind JM, Thomas AG, Bandaru VV, Yoo SW, Westwood NJ, Rogers GW, McArthur JC, Haughey NJ, Slusher BS, Rojas C. Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties. PLoS One. 2015 May 26;10(5):e0124481. doi: 10.1371/journal.pone.0124481. eCollection 2015. PubMed PMID: 26010541; PubMed Central PMCID: PMC4444023.

3: Mahajan SS, Scian M, Sripathy S, Posakony J, Lao U, Loe TK, Leko V, Thalhofer A, Schuler AD, Bedalov A, Simon JA. Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors. J Med Chem. 2014 Apr 24;57(8):3283-94. doi: 10.1021/jm4018064. Epub 2014 Apr 15. PubMed PMID: 24697269; PubMed Central PMCID: PMC4002067.

4: Medda F, Russell RJ, Higgins M, McCarthy AR, Campbell J, Slawin AM, Lane DP, Lain S, Westwood NJ. Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem. 2009 May 14;52(9):2673-82. doi: 10.1021/jm8014298. PubMed PMID: 19419202; PubMed Central PMCID: PMC2691587.

5: Lautz TB, Naiditch JA, Clark S, Chu F, Madonna MB. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma. J Pediatr Surg. 2012 Jun;47(6):1267-71. doi: 10.1016/j.jpedsurg.2012.03.039. PubMed PMID: 22703804.

6: Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, Kollipara R, Depinho RA, Gu Y, Simon JA, Bedalov A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006 Apr 15;66(8):4368-77. PubMed PMID: 16618762.

7: Portmann S, Fahrner R, Lechleiter A, Keogh A, Overney S, Laemmle A, Mikami K, Montani M, Tschan MP, Candinas D, Stroka D. Antitumor effect of SIRT1 inhibition in human HCC tumor models in vitro and in vivo. Mol Cancer Ther. 2013 Apr;12(4):499-508. doi: 10.1158/1535-7163.MCT-12-0700. Epub 2013 Jan 21. PubMed PMID: 23339189.

8: Marshall GM, Liu PY, Gherardi S, Scarlett CJ, Bedalov A, Xu N, Iraci N, Valli E, Ling D, Thomas W, van Bekkum M, Sekyere E, Jankowski K, Trahair T, Mackenzie KL, Haber M, Norris MD, Biankin AV, Perini G, Liu T. SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet. 2011 Jun;7(6):e1002135. doi: 10.1371/journal.pgen.1002135. Epub 2011 Jun 16. PubMed PMID: 21698133; PubMed Central PMCID: PMC3116909.

9: Giammona LM, Panuganti S, Kemper JM, Apostolidis PA, Lindsey S, Papoutsakis ET, Miller WM. Mechanistic studies on the effects of nicotinamide on megakaryocytic polyploidization and the roles of NAD+ levels and SIRT inhibition. Exp Hematol. 2009 Nov;37(11):1340-1352.e3. doi: 10.1016/j.exphem.2009.08.004. Epub 2009 Aug 26. PubMed PMID: 19715739; PubMed Central PMCID: PMC2763937.

10: Preyat N, Leo O. Complex role of nicotinamide adenine dinucleotide in the regulation of programmed cell death pathways. Biochem Pharmacol. 2016 Feb 1;101:13-26. doi: 10.1016/j.bcp.2015.08.110. Epub 2015 Sep 3. PubMed PMID: 26343585.

11: Stenzinger A, Endris V, Klauschen F, Sinn B, Lorenz K, Warth A, Goeppert B, Ehemann V, Muckenhuber A, Kamphues C, Bahra M, Neuhaus P, Weichert W. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC Cancer. 2013 Oct 2;13:450. doi: 10.1186/1471-2407-13-450. PubMed PMID: 24088390; PubMed Central PMCID: PMC3850795.

12: Simmons GE Jr, Pandey S, Nedeljkovic-Kurepa A, Saxena M, Wang A, Pruitt K. Frizzled 7 expression is positively regulated by SIRT1 and β-catenin in breast cancer cells. PLoS One. 2014 Jun 4;9(6):e98861. doi: 10.1371/journal.pone.0098861. eCollection 2014. PubMed PMID: 24897117; PubMed Central PMCID: PMC4045932.

13: Laemmle A, Lechleiter A, Roh V, Schwarz C, Portmann S, Furer C, Keogh A, Tschan MP, Candinas D, Vorburger SA, Stroka D. Inhibition of SIRT1 impairs the accumulation and transcriptional activity of HIF-1α protein under hypoxic conditions. PLoS One. 2012;7(3):e33433. doi: 10.1371/journal.pone.0033433. Epub 2012 Mar 30. PubMed PMID: 22479397; PubMed Central PMCID: PMC3316573.

14: Ghosh A, Sengupta A, Seerapu GPK, Nakhi A, Shivaji Ramarao EVV, Bung N, Bulusu G, Pal M, Haldar D. A novel SIRT1 inhibitor, 4bb induces apoptosis in HCT116 human colon carcinoma cells partially by activating p53. Biochem Biophys Res Commun. 2017 May 17. pii: S0006-291X(17)30963-4. doi: 10.1016/j.bbrc.2017.05.089. [Epub ahead of print] PubMed PMID: 28526414.

15: Fernandes CA, Fievez L, Neyrinck AM, Delzenne NM, Bureau F, Vanbever R. Sirtuin inhibition attenuates the production of inflammatory cytokines in lipopolysaccharide-stimulated macrophages. Biochem Biophys Res Commun. 2012 Apr 20;420(4):857-61. doi: 10.1016/j.bbrc.2012.03.088. Epub 2012 Mar 24. PubMed PMID: 22469470.

16: Moscardó A, Vallés J, Latorre A, Jover R, Santos MT. The histone deacetylase sirtuin 2 is a new player in the regulation of platelet function. J Thromb Haemost. 2015 Jul;13(7):1335-44. doi: 10.1111/jth.13004. Epub 2015 Jun 11. PubMed PMID: 25960087.

17: Liang Z, Yang Y, Wang H, Yi W, Yan X, Yan J, Li Y, Feng Y, Yu S, Yang J, Jin Z, Duan W, Chen W. Inhibition of SIRT1 signaling sensitizes the antitumor activity of silybin against human lung adenocarcinoma cells in vitro and in vivo. Mol Cancer Ther. 2014 Jul;13(7):1860-72. doi: 10.1158/1535-7163.MCT-13-0942. Epub 2014 May 5. PubMed PMID: 24798868.

18: Holloway KR, Barbieri A, Malyarchuk S, Saxena M, Nedeljkovic-Kurepa A, Cameron Mehl M, Wang A, Gu X, Pruitt K. SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression. Mol Endocrinol. 2013 Mar;27(3):480-90. doi: 10.1210/me.2012-1347. Epub 2013 Jan 22. PubMed PMID: 23340254; PubMed Central PMCID: PMC3589668.

19: Gerhauser C. Cancer chemoprevention and nutriepigenetics: state of the art and future challenges. Top Curr Chem. 2013;329:73-132. doi: 10.1007/128_2012_360. Review. PubMed PMID: 22955508.

20: Huang J, Plass C, Gerhauser C. Cancer chemoprevention by targeting the epigenome. Curr Drug Targets. 2011 Dec;12(13):1925-56. Review. PubMed PMID: 21158707.